Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37317974.
- Also identified by DOI 10.1172/JCI171104 and PMC identifier 10266771.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Palmitoylation is a critical posttranslational modification that enables the cellular membrane localization and subsequent activation of RAS proteins, including HRAS, KRAS, and NRAS. However, the molecular mechanism that regulates RAS palmitoylation in malignant diseases remains unclear. In this issue of the JCI, Ren, Xing, and authors shed light on this topic and revealed how upregulation of RAB27B, as a consequence of CBL loss and Janus kinase 2 (JAK2) activation, contributes to leukemogenesis. The authors found that RAB27B mediated NRAS palmitoylation and plasma membrane localization by recruiting ZDHHC9. The findings suggest that targeting RAB27B could provide a promising therapeutic strategy for NRAS-driven cancers.
Medical subject headings
- Hematologic Neoplasms
- Leukemia